Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Last 14 days
A Study of Viracept in HIV-Positive Women
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
Viracept Expanded Access Program
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Viracept — VIRACEPT
Application NDA020778 (NDA)
Viracept — VIRACEPT
Application NDA020779 (NDA)
Viracept — VIRACEPT
Application NDA021503 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)